Literature DB >> 17665722

Massachusetts' approach to universal coverage: high hopes and faulty economic logic.

David U Himmelstein1, Steffie Woolhandler.   

Abstract

Massachusetts' new universal coverage law has been lauded as a national model. The legislation expands Medicaid HMOs to cover all of the poor (free of charge) and near poor (with partial subsidies), and requires the rest of the uninsured to pay for private coverage. Large employers that don't offer coverage will pay a small tax. Other provisions raise Medicaid payment rates to providers; expand some smaller programs for the poor; allow dependents to remain on family policies up to age 25; and require increased public disclosure of medical price and quality data. Unfortunately, the legislation includes grossly inadequate funding for the promised subsidies and assumes that the uninsured, most of whom are in lower-income families, can afford substantial premiums. Moreover, the required coverage will leave gaping holes--co-payments and deductibles that will leave families vulnerable to bankruptcy. All of the new coverage will be purchased from private insurers with high overhead costs. The bill includes no credible cost-containment mechanisms. The legislation reflects a political calculus favoring private insurers, and ignores the imperative of cost control and the financial realities of cash-strapped families. Hence, it is unlikely to achieve universal coverage or to stabilize the state's health care financing system.

Entities:  

Mesh:

Year:  2007        PMID: 17665722     DOI: 10.2190/Q81U-215K-6570-5121

Source DB:  PubMed          Journal:  Int J Health Serv        ISSN: 0020-7314            Impact factor:   1.663


  2 in total

1.  The pharmaceutical regulation of chronic disease among the U.S. urban poor: an ethnographic study of accountability.

Authors:  Susan J Shaw
Journal:  Crit Public Health       Date:  2017-05-29

2.  Only half the problem is being addressed: underinsurance is as big a problem as uninsurance.

Authors:  Carol L Link; John B McKinlay
Journal:  Int J Health Serv       Date:  2010       Impact factor: 1.663

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.